WT1 transcription factor
Senast uppdaterad 27 okt 2023
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ljudversion
- Lägg till i föredragna källor på Google
Den WT1 gene provides instructions for making a protein that is necessary for the development of the kidneys and gonads (ovaries in females and testes in males) before birth. After birth, WT1 protein activity is limited to a structure known as the glomerulus, which filters blood through the kidneys. The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). To carry out these functions, the WT1 protein regulates the activity of other genes by attaching (binding) to specific regions of DNA. On the basis of this action, the WT1 protein is called a transcription factor.
Normal function
Den WT1 gene provides instructions for making a protein that is necessary for the development of the kidneys and gonads (ovaries in females and testes in males) before birth. After birth, WT1 protein activity is limited to a structure known as the glomerulus, which filters blood through the kidneys. The WT1 protein plays a role in cell growth, the process by which cells mature to perform specific functions (differentiation), and the self-destruction of cells (apoptosis). To carry out these functions, the WT1 protein regulates the activity of other genes by attaching (binding) to specific regions of DNA. On the basis of this action, the WT1 protein is called a transcription factor.
Conditions referring to this gene or chromosome
Other names
WIT-2
WT1_HUMAN
WT33
Related patient information and medicines
Patient information leaflet
Akut myeloisk leukemi
Akut myeloisk leukemi is where the bone marrow makes large numbers of abnormal immature white blood cells which are derived from a myeloid stem cell. What is acute myeloid leukaemia. Acute myeloid leukaemia (AML) is a condition where the bone marrow makes large numbers of abnormal immature white blood cells which are derived from a myeloid stem.
Patient information leaflet
Akut lymfatisk leukemi
The main treatment is chemotherapy, someti... Stem cell transplant (SCT) is sometimes performed. The exact treatment regime used in each case (the medicines used, doses, length of treatment, etc) takes into account various factors. In some cases, radiotherapy to the brain is also used. Stem cell transplantation (SCT) SCT - sometimes called bone.
Patient information leaflet
Hemofili
Hemofili is a rare bleeding disorder that affects your ability to make a clot. The blood contains substances called clotting factors that work with platelets to form a clot. When you injure yourself the clot stops you bleeding. Haemophilia is a condition where there is a deficiency of clotting factors, so people with this condition usually have.
Patient information leaflet
Trombofili
These blood clots can cause problems such as deep vein thrombosis (DVT) or pulmonary embolism. The clotting cascade makes the blood solidify into a clot, which sticks to the injured part of the blood vessel. Small particles in the blood, called platelets, also help to form the clot. There may be too much of a clotting factor, or too little of a.
Patient information leaflet
Kan jag ta Apixaban och Rybelsus tillsammans?
These two medicines work in different ways and do not typically interfere with how the other is absorbed, broken down, or removed from the body. Why this happens Apixaban is an anticoagulant (blood thinner) that works by blocking a clotting factor called Factor Xa. Rybelsus is a GLP-1 receptor agonist used for typ 2 diabetes that mimics a natural.
Patient information leaflet
Blodproppstester
Blodproppstester are used to diagnose and assess bleeding problems and to monitor people who take warfarin or other anticoagulant medicines. You may be advised to have blood clotting tests: If you have a suspected bleeding disorder. For example, if you bleed a lot after cuts, or if you bruise easily. If you have certain liver diseases that can.
Vidare läsning och referenser
- WT1 transcription factor; MedlinePlus, National Library of Medicine.
- Al-Hussain T, Ali A, Akhtar M. Wilms tumor: an update. Adv Anat Pathol. 2014 May;21(3):166-73. doi: 10.1097/PAP.0000000000000017.
- Andrade JG, Guaragna MS, Soardi FC, Guerra-Junior G, Mello MP, Maciel-Guerra AT. Clinical and genetic findings of five patients with WT1-related disorders. Arq Bras Endocrinol Metabol. 2008 Nov;52(8):1236-43. doi: 10.1590/s0004-27302008000800006.
- Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007 May 24;9(14):1-17. doi: 10.1017/S1462399407000336.
- Deng C, Dai R, Li X, Liu F. Genetic variation frequencies in Wilms' tumor: A meta-analysis and systematic review. Cancer Sci. 2016 May;107(5):690-9. doi: 10.1111/cas.12910. Epub 2016 Mar 18.
- Heathcott RW, Morison IM, Gubler MC, Corbett R, Reeve AE. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X. Hum Mutat. 2002 Apr;19(4):462. doi: 10.1002/humu.9031.
- Miller-Hodges E, Hohenstein P. WT1 in disease: shifting the epithelial-mesenchymal balance. J Pathol. 2012 Jan;226(2):229-40. doi: 10.1002/path.2977. Epub 2011 Sep 29.
- Salvatorelli L, Parenti R, Leone G, Musumeci G, Vasquez E, Magro G. Wilms tumor 1 (WT1) protein: Diagnostic utility in pediatric tumors. Acta Histochem. 2015 May-Jun;117(4-5):367-78. doi: 10.1016/j.acthis.2015.03.010. Epub 2015 Apr 14.
- Suri M, Kelehan P, O'neill D, Vadeyar S, Grant J, Ahmed SF, Tolmie J, McCann E, Lam W, Smith S, Fitzpatrick D, Hastie ND, Reardon W. WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of the cardiac and diaphragmatic malformations. Am J Med Genet A. 2007 Oct 1;143A(19):2312-20. doi: 10.1002/ajmg.a.31924.
- Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007 May;21(5):868-76. doi: 10.1038/sj.leu.2404624. Epub 2007 Mar 15.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
27 okt 2023 | Senaste versionen
1 Sept 2018 | Ursprungligen publicerad
Delta i konversationen
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Fråga, dela, anslut.
Bläddra i diskussioner, ställ frågor och dela erfarenheter inom hundratals hälsorelaterade ämnen.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.